Place · Level 3 · Condition
Hepatitis B · 75 million quiet housemates
病毒把存档藏进细胞核, 所以治得住却清不掉 · 伤肝的是免疫系统不是病毒 · 共餐握手不传染, 因为它需要一个破口 · 出生 24 小时内的两针, 抢在病毒归档之前 · 半年一次超声胜过任何保肝药
Story path
- 1cccDNA · the master copy in the nucleuscccDNA · the master copy in the nucleus
- 2It isn't the virus that hurts the liverIt isn't the virus that hurts the liver
- 3Four phases · what the serology meansFour phases · what the serology means
- 4Two roads to liver cancerTwo roads to liver cancer
- 5The first 24 hours · beating the virus to the archiveThe first 24 hours · beating the virus to the archive
- 6A carrier's reality · follow-up beats liver pillsA carrier's reality · follow-up beats liver pills
Chapter 1
cccDNA · the master copy in the nucleus
cccDNA · the master copy in the nucleus
Hepatitis B virus can be pinned down by drugs but almost never cleared. The reason isn't that the drugs are weak — it's that the virus has filed its master copy inside the nucleus of your liver cells.
Once the virus gets into a liver cell, the first important thing it does isn't to replicate — it's to archive. It sends its loose circular DNA into the nucleus, repairs the gaps, seals it into a fully closed little ring, wraps it in protein, and parks it alongside your own chromosomes. This thing is called cccDNA, and it is a viral mini-chromosome (Nassal 2015).
Once filed, it sits quietly in the nucleus as the master copy. Every time a new batch of virus is needed, the nucleus transcribes RNA off that master, ships it to the cytoplasm, reverse-transcribes it back into viral DNA, packages it, and ships it out.
Now look at where the drugs land. Today's first-line oral drugs (entecavir, tenofovir — the nucleos(t)ide analogues) block the reverse transcription step, i.e. the copying shop. They can push the virus in your blood below the limit of detection, which is genuinely effective. But they cannot touch the master copy in the nucleus. The master is still there, so when the drug stops, the copying shop reopens and the virus comes back (Nassal 2015; EASL 2017).
That is the molecular root of 'controllable but not curable', and it is why most people who start these drugs generally stay on them long-term.
Once the virus gets into a liver cell, the first important thing it does isn't to replicate — it's to archive. It sends its loose circular DNA into the nucleus, repairs the gaps, seals it into a fully closed little ring, wraps it in protein, and parks it alongside your own chromosomes. This thing is called cccDNA, and it is a viral mini-chromosome (Nassal 2015).
Once filed, it sits quietly in the nucleus as the master copy. Every time a new batch of virus is needed, the nucleus transcribes RNA off that master, ships it to the cytoplasm, reverse-transcribes it back into viral DNA, packages it, and ships it out.
Now look at where the drugs land. Today's first-line oral drugs (entecavir, tenofovir — the nucleos(t)ide analogues) block the reverse transcription step, i.e. the copying shop. They can push the virus in your blood below the limit of detection, which is genuinely effective. But they cannot touch the master copy in the nucleus. The master is still there, so when the drug stops, the copying shop reopens and the virus comes back (Nassal 2015; EASL 2017).
That is the molecular root of 'controllable but not curable', and it is why most people who start these drugs generally stay on them long-term.
The goal of treatment isn't seroclearance
If it can't be cleared, what is the drug actually buying? This is the thing worth settling first about hepatitis B treatment.The international guidelines say it plainly: the main goal of therapy is long-term suppression of viral replication, thereby preventing disease progression, consequently lowering cirrhosis and liver-cancer risk, and ultimately improving survival and quality of life (EASL 2017). Note what that sentence does not contain: 'eliminate the virus'.
The first-line drugs are a few potent nucleos(t)ide analogues with a high barrier to resistance: entecavir, tenofovir disoproxil, and tenofovir alafenamide (EASL 2017; WHO 2024). Their job is to hold the viral load on the floor so the immune system doesn't have to open fire every day and hepatocytes don't get killed and regrown over and over.
The ideal endpoint — surface antigen (HBsAg) also disappearing from the blood, which the field calls functional cure — is beyond current drugs; only a minority reach it spontaneously. Many drugs in development are aimed squarely at cccDNA, but as of today, any supplement, herb, or therapy claiming to turn hepatitis B negative does not hold up.
So the right way to understand taking the drug: it isn't clearing the virus, it's changing the ending.
Chapter 2
It isn't the virus that hurts the liver
It isn't the virus that hurts the liver
What damages the liver isn't the hepatitis B virus itself — it's your own immune system.
The virus lives inside liver cells making more virus, but it doesn't burst them open. Viruses like this, which don't directly kill their host cell, are called noncytopathic (Guidotti & Chisari 2006).
So how does the liver get hurt? The immune system is doing a sweep. A type of immune cell that specializes in killing infected cells (cytotoxic T lymphocytes, CTLs) patrols the liver, recognizes which hepatocytes are displaying viral markers on their surface, and kills them one by one. When a hepatocyte dies, the enzymes inside it leak into the blood — and that is where the raised ALT (alanine aminotransferase) on your lab report comes from.
So ALT doesn't measure how vicious the virus is. It measures how hard the immune system is fighting.
That single fact explains two very counter-intuitive things:
Viral load sky-high, liver function perfectly normal. Common in young carriers infected at birth. The immune system hasn't registered the virus as an enemy yet; no fighting, no liver damage. The virus in the blood can be frighteningly high while ALT stays normal throughout.A sudden spike in transaminases actually means the immune system has started working. It is the noise of a battle, not the virus getting stronger.
Push one layer further and the nature of chronic hepatitis B comes clear: it is an unfinishable war. The immune response isn't strong enough to clear the virus outright, yet it keeps killing cells — so hepatocytes are killed and regrown, over and over (Guidotti & Chisari 2006). Drag that cycle out for decades and you have the soil in which fibrosis and liver cancer later grow.
The virus lives inside liver cells making more virus, but it doesn't burst them open. Viruses like this, which don't directly kill their host cell, are called noncytopathic (Guidotti & Chisari 2006).
So how does the liver get hurt? The immune system is doing a sweep. A type of immune cell that specializes in killing infected cells (cytotoxic T lymphocytes, CTLs) patrols the liver, recognizes which hepatocytes are displaying viral markers on their surface, and kills them one by one. When a hepatocyte dies, the enzymes inside it leak into the blood — and that is where the raised ALT (alanine aminotransferase) on your lab report comes from.
So ALT doesn't measure how vicious the virus is. It measures how hard the immune system is fighting.
That single fact explains two very counter-intuitive things:
Viral load sky-high, liver function perfectly normal. Common in young carriers infected at birth. The immune system hasn't registered the virus as an enemy yet; no fighting, no liver damage. The virus in the blood can be frighteningly high while ALT stays normal throughout.A sudden spike in transaminases actually means the immune system has started working. It is the noise of a battle, not the virus getting stronger.
Push one layer further and the nature of chronic hepatitis B comes clear: it is an unfinishable war. The immune response isn't strong enough to clear the virus outright, yet it keeps killing cells — so hepatocytes are killed and regrown, over and over (Guidotti & Chisari 2006). Drag that cycle out for decades and you have the soil in which fibrosis and liver cancer later grow.
High viral load, normal ALT · what this phase is called
That state above — huge amounts of virus, an apparently untroubled liver — isn't a coincidence. It's a named phase in the natural history.International guidelines now call it HBeAg-positive chronic infection (formerly the immune-tolerant phase), defined by three things holding at once: HBeAg positive, very high viral load (HBV DNA typically above 10⁷ IU/mL), and persistently normal ALT (EASL 2017). It's mostly seen under age 30; someone infected perinatally can sit in this phase for two or three decades before the immune-active phase begins.
Most guidelines do not recommend antiviral therapy in this phase — the immune system isn't cooperating, so the drug's benefit is limited.
But please do not read 'no drug' as 'nothing wrong'. Two reasons:
1. The liver isn't necessarily clean in this phase. Histology studies find that among people meeting immune-tolerant criteria, some already have meaningful inflammation or fibrosis.
2. More importantly, integration of viral DNA into the host genome is already happening early — it doesn't wait for the immune system to engage (Hai 2014). Integration is the fast road to liver cancer described later.
One more thing is moving: both China's 2022 guideline and WHO's 2024 guideline are widening treatment eligibility (Chinese Medical Association 2022; WHO 2024). So whether this phase warrants a drug is an answer that has been shifting.
The conclusion is simple: 'no drug' does not mean 'no follow-up'.
Chapter 3
Four phases · what the serology means
Four phases · what the serology means
Many people getting a hepatitis B report ask one question first: am I 'big three positive' or 'small three positive'? But those two folk terms only describe a combination on a lab sheet — they do not by themselves equal mild or severe. What determines the disease is which phase of the natural history you have reached.
Chronic hepatitis B isn't a static state; it's a road that moves. Clinicians work out which stretch you're on from three things: viral load (HBV DNA), whether the e antigen (HBeAg) is present, and whether ALT is raised (EASL 2017).
Immune system hasn't engaged: HBeAg positive, viral load very high, ALT normal. Lots of virus, liver fine for now.Immune system engaged: HBeAg still there, viral load high, ALT fluctuating upward. This is the most actively damaging period.Half the battle won: the immune system pushes HBeAg down and the body switches to making e antibody instead. That step is called HBeAg seroconversion. Viral load falls, ALT returns to normal, the liver enters a relatively quiet phase.May reactivate: in some people it flares again years later — HBeAg still negative, but viral load and ALT both climb back up.
Once you see the road, the two folk terms make sense. 'Big three positive' roughly maps to the first two stretches (HBeAg still present); 'small three positive' roughly maps to the last two (switched to e antibody).
The crux is that last stretch: among 'small three positive' people there are both the genuinely quiet and the already-reactivated. So the label itself cannot tell you whether you are safe.
Chronic hepatitis B isn't a static state; it's a road that moves. Clinicians work out which stretch you're on from three things: viral load (HBV DNA), whether the e antigen (HBeAg) is present, and whether ALT is raised (EASL 2017).
Immune system hasn't engaged: HBeAg positive, viral load very high, ALT normal. Lots of virus, liver fine for now.Immune system engaged: HBeAg still there, viral load high, ALT fluctuating upward. This is the most actively damaging period.Half the battle won: the immune system pushes HBeAg down and the body switches to making e antibody instead. That step is called HBeAg seroconversion. Viral load falls, ALT returns to normal, the liver enters a relatively quiet phase.May reactivate: in some people it flares again years later — HBeAg still negative, but viral load and ALT both climb back up.
Once you see the road, the two folk terms make sense. 'Big three positive' roughly maps to the first two stretches (HBeAg still present); 'small three positive' roughly maps to the last two (switched to e antibody).
The crux is that last stretch: among 'small three positive' people there are both the genuinely quiet and the already-reactivated. So the label itself cannot tell you whether you are safe.
The five markers · what each one says
The folk terms 'big three positive' and 'small three positive' come from the five hepatitis B markers on a check-up sheet. Go through them one by one and the mystery dissolves.Surface antigen (HBsAg) — positive = you have the virus now. This is the core item for deciding whether an infection exists.Surface antibody (anti-HBs) — positive = you have protection. Either you were vaccinated, or you cleared an infection yourself.e antigen (HBeAg) — positive = replication is active, infectivity relatively high.e antibody (anti-HBe) — positive = usually means replication has weakened.Core antibody (anti-HBc) — positive = you have been infected. Note: vaccination does not turn this one positive, so it distinguishes 'vaccinated' from 'had hepatitis B'.
So the two folk terms are simply:
Big three positive = surface antigen + e antigen + core antibody, all three positive.Small three positive = surface antigen + e antibody + core antibody, all three positive.
As you can see, the only difference is whether the middle item is e antigen or e antibody. That reflects one facet of replication activity — not a disease stage, and certainly not a severity score (Chinese Medical Association 2022; EASL 2017).
The three numbers that actually matter are: viral load, ALT, and degree of fibrosis.
Why 'small three positive' isn't automatic reassurance
'Small three positive' is most easily misread as 'the virus has gone mild'. Sometimes that's true; sometimes it's the opposite. The difference comes from a virological accident.In 1989, Carman and colleagues found the reason in a set of chronic hepatitis B patients who were HBeAg-negative yet still had detectable virus: a point mutation (G1896A) in the virus's precore region that introduces a premature stop codon into that sequence (Carman 1989).
The consequence is the crux: this mutation knocks out only the production line for e antigen and does nothing to the virus's ability to replicate itself. The result is a viral strain that cannot make e antigen but still replicates, still draws immune fire, and still damages the liver.
That is the fourth stretch of the natural history: HBeAg-negative chronic hepatitis. The lab sheet says 'small three positive', but the viral load isn't low and ALT is climbing. Guidelines list this as a category to be evaluated for treatment — not a mild variant (EASL 2017; Chinese Medical Association 2022).
So the correct reading is: 'small three positive' only says the e antigen is gone. It might mean the immune system won half the battle, or it might mean the virus changed its recipe. Telling those apart takes viral load, ALT, and fibrosis assessment — not a label.
carman-1989-lancet-precore-mutant
Chapter 4
Two roads to liver cancer
Two roads to liver cancer
Hepatitis B reaches liver cancer by two roads — and one of them doesn't pass through cirrhosis. Understanding that difference explains why the follow-up rules for hepatitis B differ from other liver diseases.
The slow road · scars worn in by repeated inflammation. The immune system kills hepatocytes round after round; the liver regenerates round after round. During repair, stellate cells in the liver are woken up and start laying down collagen. Scar piles on scar — that's fibrosis, ending in cirrhosis. In a cirrhotic liver, cells divide frequently and genetic errors are likelier, and liver cancer grows out of that rubble. This stretch runs through the same channel as fatty liver and alcoholic liver disease — for a close look at how the scar gets laid down, go to the nafld island.
The fast road · the virus welds itself into your genome. This road is hepatitis B's own trick. The virus's DNA integrates into the hepatocyte's chromosomes, inserting itself right into the middle of your own genes. Once inserted, it is no longer merely an infection — it has become part of your genome: it may shove the neighboring gene aside, or express a cancer-promoting protein itself. In hepatitis-B-related liver cancers, integrated viral DNA is found in 85% to 90% (Hai 2014). One of the most frequently hit hotspots is the switch for the gene controlling cellular immortalization (the TERT promoter).
The trouble with the fast road: integration can happen very early and doesn't wait for cirrhosis. So hepatitis B can grow a liver cancer while the liver has not yet become cirrhotic — this has been seen in children and young adults (Hai 2014).
That one fact is why liver-cancer screening in hepatitis B carriers doesn't wait for cirrhosis the way it does in other liver diseases. The broader relationship between food and cancer is a separate matter — that's on the cancer-nutrition island.
The slow road · scars worn in by repeated inflammation. The immune system kills hepatocytes round after round; the liver regenerates round after round. During repair, stellate cells in the liver are woken up and start laying down collagen. Scar piles on scar — that's fibrosis, ending in cirrhosis. In a cirrhotic liver, cells divide frequently and genetic errors are likelier, and liver cancer grows out of that rubble. This stretch runs through the same channel as fatty liver and alcoholic liver disease — for a close look at how the scar gets laid down, go to the nafld island.
The fast road · the virus welds itself into your genome. This road is hepatitis B's own trick. The virus's DNA integrates into the hepatocyte's chromosomes, inserting itself right into the middle of your own genes. Once inserted, it is no longer merely an infection — it has become part of your genome: it may shove the neighboring gene aside, or express a cancer-promoting protein itself. In hepatitis-B-related liver cancers, integrated viral DNA is found in 85% to 90% (Hai 2014). One of the most frequently hit hotspots is the switch for the gene controlling cellular immortalization (the TERT promoter).
The trouble with the fast road: integration can happen very early and doesn't wait for cirrhosis. So hepatitis B can grow a liver cancer while the liver has not yet become cirrhotic — this has been seen in children and young adults (Hai 2014).
That one fact is why liver-cancer screening in hepatitis B carriers doesn't wait for cirrhosis the way it does in other liver diseases. The broader relationship between food and cancer is a separate matter — that's on the cancer-nutrition island.
Viral load sets the risk · numbers from REVEAL
'High viral load = high risk' isn't a deduction — it was counted. The data come mainly from Taiwan's REVEAL-HBV cohort.Liver cancer (Chen 2006, JAMA): 3,653 surface-antigen-positive people followed for over a decade. Stratified by viral load at entry, HCC incidence showed a continuous dose-response:
viral load < 300 copies/mL: 108 per 100,000 person-yearsviral load ≥ 1 million copies/mL: 1,152 per 100,000 person-years
More than a tenfold gap — and the relationship held independent of HBeAg status and ALT level.
Cirrhosis (Iloeje 2006, Gastroenterology): 3,582 people from the same cohort, mean follow-up 11 years. Cumulative cirrhosis incidence tracked viral load the same way: from 4.5% at < 300 copies/mL to 36.2% above 10⁶ copies/mL.
e antigen (Yang 2002, NEJM): a prospective study of 11,893 men found HBeAg positivity associated with raised liver-cancer risk.
Be honest about evidence grade: all three are prospective cohorts (grade B), not randomized trials. But they corroborate each other, and crucially viral load is modifiable — a point randomized evidence supplied: Liaw 2004 (NEJM) randomized hepatitis B patients with advanced fibrosis or cirrhosis to lamivudine or placebo, and the treated group's rate of hepatic decompensation was roughly halved, with liver-cancer incidence moving in a similar direction.
Read together, these are the foundation of modern hepatitis B management: viral load sets the risk, drugs change viral load, therefore drugs change the risk.
iloeje-2006-reveal-viral-load-cirrhosisyang-2002-nejm-hbeag-hcc-riskliaw-2004-nejm-lamivudine-advanced-disease
Chapter 5
The first 24 hours · beating the virus to the archive
The first 24 hours · beating the virus to the archive
The two shots given on the day of birth are racing a gap of only a few dozen hours. Win the race and this child's life has nothing to do with hepatitis B; lose it and lifelong carriage is the likely outcome.
First, why newborns are in such danger. Hepatitis B has an age rule that sounds backwards: the younger you are when infected, the likelier it becomes a lifelong chronic infection. Of infants infected perinatally, roughly 80-90% become chronic; of children infected before age 6, about 30%; whereas healthy adults infected later clear the virus on their own more than 90% of the time (Hyams 1995; WHO 2022).
The baby with the weaker immune system is the one more likely to carry it long-term — which makes sense the moment you connect it to the previous scene: it's the immune system that damages the liver. When an adult is infected, the immune system recognizes the intruder at once and opens fire, clearing hepatocytes that display viral markers along with the virus inside them. The price is an acute hepatitis: some yellowing, some weeks of fatigue, and then it's over. A newborn's immune system is still in its learning who's who phase. It hasn't registered this virus as an enemy, so it doesn't open fire. No fire means no inflammation, and the lab sheet stays normal throughout — and the virus quietly moves in for decades (Guidotti & Chisari 2006).
The same virus is a few months' illness in an adult and a lifelong condition in a newborn. The difference isn't how vicious the virus is — it's whether it gets recognized.
Second, why the window is only a day wide. Back to the first scene: once the virus gets into a liver cell and files its master copy in the nucleus, antibodies can never reach it again. Antibodies swim in the blood; they don't get inside cells (Nassal 2015).
So antibodies get exactly one chance — to already be waiting in the blood before the virus makes landfall, and catch it in transit. Exposure at birth is a single, large dose; from that moment the viral particles in the blood are on their way to the liver. That is the length of the gap. Which is why the World Health Organization's recommendation is stated so firmly: the first dose as early as possible, preferably within 24 hours of birth (WHO 2024). A day late isn't a discount — it can mean the whole thing was for nothing.
Third, why it takes both shots. The two do completely different jobs.
Hepatitis B immunoglobulin (HBIG) — antibodies already made in someone else's body, injected straight into the baby's blood. In position within hours, they grab viral particles on the spot so they can't dock at the liver cell's door. This is passive immunity: borrowed troops. Fast, which is the point; but these antibodies are slowly metabolized away, they only hold for a few weeks, and they teach the baby nothing.Hepatitis B vaccine — what goes in isn't virus, only the virus's coat protein, the same surface antigen your lab sheet reports. The baby's immune cells must first learn it, then expand, then make antibodies of their own, and that takes weeks. This is active immunity: slow, but once learned it is remembered, and it protects for decades.
One is fast and short, the other slow and long, and they join up exactly in time. HBIG holds the most dangerous first weeks while the baby's own antibodies grow up to take over.
This isn't reasoning on paper. In a meta-analysis pooling 12 randomized trials, vaccine plus HBIG versus vaccine alone cut the risk of the infant being surface-antigen positive by roughly half again (RR 0.54, Jin 2014).
Blocking that one day blocks more than an infection. No chronic infection means no decades-long immune tug-of-war, and no fast road of integration into the genome from the previous scene. After universal vaccination in Taiwan, annual liver-cancer incidence in children aged 6 to 14 fell from 0.70 to 0.36 per 100,000 (Chang 1997). A shot aimed at a virus blocked a cancer.
First, why newborns are in such danger. Hepatitis B has an age rule that sounds backwards: the younger you are when infected, the likelier it becomes a lifelong chronic infection. Of infants infected perinatally, roughly 80-90% become chronic; of children infected before age 6, about 30%; whereas healthy adults infected later clear the virus on their own more than 90% of the time (Hyams 1995; WHO 2022).
The baby with the weaker immune system is the one more likely to carry it long-term — which makes sense the moment you connect it to the previous scene: it's the immune system that damages the liver. When an adult is infected, the immune system recognizes the intruder at once and opens fire, clearing hepatocytes that display viral markers along with the virus inside them. The price is an acute hepatitis: some yellowing, some weeks of fatigue, and then it's over. A newborn's immune system is still in its learning who's who phase. It hasn't registered this virus as an enemy, so it doesn't open fire. No fire means no inflammation, and the lab sheet stays normal throughout — and the virus quietly moves in for decades (Guidotti & Chisari 2006).
The same virus is a few months' illness in an adult and a lifelong condition in a newborn. The difference isn't how vicious the virus is — it's whether it gets recognized.
Second, why the window is only a day wide. Back to the first scene: once the virus gets into a liver cell and files its master copy in the nucleus, antibodies can never reach it again. Antibodies swim in the blood; they don't get inside cells (Nassal 2015).
So antibodies get exactly one chance — to already be waiting in the blood before the virus makes landfall, and catch it in transit. Exposure at birth is a single, large dose; from that moment the viral particles in the blood are on their way to the liver. That is the length of the gap. Which is why the World Health Organization's recommendation is stated so firmly: the first dose as early as possible, preferably within 24 hours of birth (WHO 2024). A day late isn't a discount — it can mean the whole thing was for nothing.
Third, why it takes both shots. The two do completely different jobs.
Hepatitis B immunoglobulin (HBIG) — antibodies already made in someone else's body, injected straight into the baby's blood. In position within hours, they grab viral particles on the spot so they can't dock at the liver cell's door. This is passive immunity: borrowed troops. Fast, which is the point; but these antibodies are slowly metabolized away, they only hold for a few weeks, and they teach the baby nothing.Hepatitis B vaccine — what goes in isn't virus, only the virus's coat protein, the same surface antigen your lab sheet reports. The baby's immune cells must first learn it, then expand, then make antibodies of their own, and that takes weeks. This is active immunity: slow, but once learned it is remembered, and it protects for decades.
One is fast and short, the other slow and long, and they join up exactly in time. HBIG holds the most dangerous first weeks while the baby's own antibodies grow up to take over.
This isn't reasoning on paper. In a meta-analysis pooling 12 randomized trials, vaccine plus HBIG versus vaccine alone cut the risk of the infant being surface-antigen positive by roughly half again (RR 0.54, Jin 2014).
Blocking that one day blocks more than an infection. No chronic infection means no decades-long immune tug-of-war, and no fast road of integration into the genome from the previous scene. After universal vaccination in Taiwan, annual liver-cancer incidence in children aged 6 to 14 fell from 0.70 to 0.36 per 100,000 (Chang 1997). A shot aimed at a virus blocked a cancer.
Sharing a meal does not transmit it · let's settle this
Hepatitis B travels by blood, not through the digestive tract.Concretely: for the virus to infect you, it must get into your blood. It has exactly three routes (WHO 2022; WHO 2024):
Blood exposure — shared needles, unregulated tattooing and piercing, unsafe medical or dental procedures, shared razors and other personal items that can carry blood.Mother to child — transmission at birth, historically the dominant route in high-prevalence regions.Sexual contact — unprotected sex.
It is not transmitted by: sharing a meal, sharing utensils, shaking hands, hugging, kissing, coughing, sneezing, food, water, or breastmilk. The World Health Organization's own words: HBV is not spread through breastmilk, food or water, or by casual contact such as hugging, kissing or sharing food or drink with an infected person (WHO 2022).
The mechanism agrees. Your digestive tract is a tube open to the outside; stomach acid and the gut wall keep almost everything out of the bloodstream. Hepatitis B virus has no ability to bore from the gut lumen into the blood — it needs a breach.
Here is a useful contrast. Helicobacter pylori, also common in China, does spread through shared eating, because its battlefield is the stomach and the digestive tract is exactly its road; that island is at h-pylori-gastric-cancer. Two diseases, two roads, entirely different. Applying H. pylori's rules to hepatitis B applies the wrong rules.
This misunderstanding has not been harmless. It has kept many people out of schools and jobs over a single lab sheet — and the reason they were kept out does not exist in virology. Sharing a meal involves no breach, and without a breach there is no road. Studying together, working together, and eating together do not transmit hepatitis B; this is not an open question (WHO 2022). So testing for hepatitis B in admission and employment physicals prevents nothing.
So: eating with, working alongside, and hugging a person with hepatitis B is safe. This is not kindly reassurance — it is virology.
There is exactly one thing that genuinely should be done: family members and partners should get tested, and those without antibodies should be vaccinated (WHO 2024). Guard the road that needs guarding, not the dinner table.
Chapter 6
A carrier's reality · follow-up beats liver pills
A carrier's reality · follow-up beats liver pills
After a hepatitis B diagnosis, the most valuable thing to do isn't to buy a drug — it's to put regular follow-up in your calendar.
When does it need treating? The answer has been moving for several years, and moving toward wider eligibility. It used to require high viral load, high transaminases, and evidence of liver damage all at once; both China's 2022 guideline and WHO's 2024 guideline expanded and simplified the criteria (Chinese Medical Association 2022; WHO 2024). WHO estimates the new criteria could raise the share of people eligible for treatment from 8-15% to about 50%.
That sentence matters especially to one group: if you were told years ago that you didn't need treatment, it's worth being re-assessed against today's criteria. Whether to treat is a clinician's judgment across viral load, ALT, fibrosis stage, age, and family history — not something to decide from a lab sheet yourself.
What do untreated people do? Follow-up. And follow-up is itself the intervention.
Why is an ultrasound plus alpha-fetoprotein (AFP) every 6 months worth more than any liver pill? Because early liver cancer has no symptoms at all — by the time you feel something, the best window has usually passed — whereas liver cancer found early can be cured. The screening method guidelines recommend for high-risk people is exactly abdominal ultrasound plus AFP, every 6 months (Terrault 2018; Chinese Medical Association 2022).
Remember hepatitis B's peculiarity too: because of that fast road via integration, high-risk carriers need screening even without cirrhosis (Terrault 2018). This differs from the fatty-liver rule of waiting until F3 to start.
That twice-yearly ultrasound is the highest-value thing on this entire island.
When does it need treating? The answer has been moving for several years, and moving toward wider eligibility. It used to require high viral load, high transaminases, and evidence of liver damage all at once; both China's 2022 guideline and WHO's 2024 guideline expanded and simplified the criteria (Chinese Medical Association 2022; WHO 2024). WHO estimates the new criteria could raise the share of people eligible for treatment from 8-15% to about 50%.
That sentence matters especially to one group: if you were told years ago that you didn't need treatment, it's worth being re-assessed against today's criteria. Whether to treat is a clinician's judgment across viral load, ALT, fibrosis stage, age, and family history — not something to decide from a lab sheet yourself.
What do untreated people do? Follow-up. And follow-up is itself the intervention.
Why is an ultrasound plus alpha-fetoprotein (AFP) every 6 months worth more than any liver pill? Because early liver cancer has no symptoms at all — by the time you feel something, the best window has usually passed — whereas liver cancer found early can be cured. The screening method guidelines recommend for high-risk people is exactly abdominal ultrasound plus AFP, every 6 months (Terrault 2018; Chinese Medical Association 2022).
Remember hepatitis B's peculiarity too: because of that fast road via integration, high-risk carriers need screening even without cirrhosis (Terrault 2018). This differs from the fatty-liver rule of waiting until F3 to start.
That twice-yearly ultrasound is the highest-value thing on this entire island.
Dismantling a few widespread claims
Claims cluster thickly around hepatitis B. Let's take them one at a time.Can liver pills, liver-protecting teas, or milk thistle turn hepatitis B negative? No. No herb or supplement has been shown to clear hepatitis B virus. Milk thistle (silymarin) is the most common ingredient in liver pills, and a Cochrane systematic review pooling randomized trials in alcoholic and hepatitis B or C liver disease found that — combining all trials, or looking only at high-quality trials — no significant effect on mortality or complications of liver disease could be demonstrated (Rambaldi 2007). The whole liver-supplement market is covered more fully on the hepatic island.Is 'small three positive' milder than 'big three positive', so it can be ignored? Not necessarily. The precore mutant cannot make e antigen yet still replicates and still damages the liver (Carman 1989). What matters is viral load, ALT, and fibrosis — not the label.Does a normal ALT mean everything's fine? Not necessarily. In the phase before the immune system engages, viral load can be enormous while ALT stays normal throughout (EASL 2017). ALT measures how hard the immune system is fighting, not how much virus there is.Do people with hepatitis B just need to drink a bit less? Alcohol on top of hepatitis B isn't additive so much as multiplicative. A case-control study found liver-cancer risk rising linearly with daily alcohol intake, and the risk amplified further when hepatitis B was also present (Donato 2002). The evidence is grade C (a single case-control study; association, not causation), but the direction is consistent and the mechanism coherent: both are slowly grinding down the same organ. For how ethanol is metabolized in the liver, see the alcohol-metabolism island. For a hepatitis B carrier, the simplest answer is not to drink.Does hepatitis B always become liver cancer? No. Excess panic is harm in the other direction. WHO's estimate: about 20% to 30% of chronically infected people go on to develop cirrhosis and/or liver cancer (WHO 2022). That number is serious enough to deserve real follow-up — but it is a long way from 'always'.
rambaldi-2007-cochrane-milk-thistlecarman-1989-lancet-precore-mutantdonato-2002-alcohol-hbv-hcc-synergy
Red flags · when to see a doctor now
If any of these appear, seek care immediately. They signal hepatic decompensation and are not in the 'let's keep watching' category:Yellowing of the skin or the whites of the eyes (jaundice)Markedly distended abdomen (ascites)Vomiting blood or passing black stools (GI bleeding)Confusion, unusual drowsiness, abnormal behavior (hepatic encephalopathy)
Two more things warrant going to a doctor proactively — and in advance:
Before any immunosuppressant or chemotherapy, get tested for hepatitis B. Once immunity is suppressed, a previously quiet virus can reactivate and cause severe or even fatal hepatitis — because that master copy in the nucleus has been there all along (Nassal 2015). This is preventable: tell your doctor you're a carrier ahead of time, and take prophylaxis if indicated.If someone at home is a carrier, family members and partners should be tested, and those without antibodies should be vaccinated (WHO 2024).
The honest close. This page is education to help you understand the why — it is not medical advice. Hepatitis B management is highly individual: viral load, ALT, fibrosis, age, family history, pregnancy, and whether immunosuppressants are needed all change the answer. Decide these together with a hepatologist or infectious-disease physician.
One last thing. Carrying hepatitis B is not a moral matter, and it is not a verdict. Of roughly 75 million infected people in China, only about 58.8% know they are positive; and among those with an indication for treatment, only about 17.3% are actually receiving antiviral therapy (Yan 2025). The gap between those two numbers is the real problem this disease poses in China — not who to avoid, but that too many people don't know they're positive, and too many who do know aren't in regular follow-up.
Know, then check every six months. That carries more weight than any box of liver pills on any shelf.
yan-2025-china-hbv-epidemiology